Literature DB >> 10580196

Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1.

S Matsumoto1, H Yukitake, H Kanbara, T Yamada.   

Abstract

Previously, we constructed a recombinant live BCG (rBCG) secreting a 15 kDa C-terminal region of MSP-1 from Plasmodium yoelii (MSP-1(15)) and succeeded in the induction of more efficient protective immunity against parasite infection than observed with artificial adjuvants (Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP-1) induces protection against rodent malaria parasite infection depending on MSP-1-stimulated interferon gamma and parasite-specific antibodies. J Exp Med 1998;188:845-54 [1]). In this study, we examined the endurance of the protective effects. The protective effect generated by rBCGMSP-1(15) was observed even 9 months after final immunization, whereas the effects of immunization by MSP-1(15) together with incomplete Freund adjuvant (IFA) were found to last only 4 months.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580196     DOI: 10.1016/s0264-410x(99)00326-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

2.  Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea.

Authors:  J W Park; S H Moon; J S Yeom; K J Lim; M J Sohn; W C Jung; Y J Cho; K W Jeon; W Ju; C S Ki; M D Oh; K Choe
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

3.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 4.  Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Authors:  Nicola Clementi; Nicasio Mancini; Laura Solforosi; Matteo Castelli; Massimo Clementi; Roberto Burioni
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

5.  Interferon-gamma responses to Plasmodium falciparum liver-stage antigen-1 and merozoite-surface protein-1 increase with age in children in a malaria holoendemic area of western Kenya.

Authors:  Kiprotich Chelimo; Peter O Sumba; James W Kazura; Ayub V Ofula; Chandy C John
Journal:  Malar J       Date:  2003-11-05       Impact factor: 2.979

Review 6.  Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis.

Authors:  Reginaldo G Bastos; Heba F Alzan; Vignesh A Rathinasamy; Brian M Cooke; Odir A Dellagostin; Raúl G Barletta; Carlos E Suarez
Journal:  Vaccines (Basel)       Date:  2022-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.